Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106614 | 0.89 | NRP1 (0.55) | NRP1ALDH1A1SLC10A6LMNAPARP14 | |
| SCHEMBL4572259 | 0.83 | NRP1 (0.49) | NRP1ALDH1A1SLC10A6LMNAHPGD | |
| SCHEMBL10083054 | 0.75 | NRP1 (0.48) | NRP1ALDH1A1SLC10A6LMNAHPGD | |
| SCHEMBL2106178 | 0.75 | NRP1 (0.70) | NRP1ALDH1A1NPR1 | |
| SCHEMBL13547968 | 0.72 | SLC10A6 (0.52) | NRP1ALDH1A1SLC10A6LMNAPARP14 | |
| SCHEMBL4569808 | 0.72 | NRP1 (0.75) | NRP1ALDH1A1NPR1 | |
| SCHEMBL2106421 | 0.64 | NRP1 (0.71) | NRP1SLC10A6PARP14NPR1 | |
| SCHEMBL4569812 | 0.62 | NRP1 (0.62) | NRP1LMNAHPGDTSHRNPR1 | |
| SCHEMBL4569795 | 0.61 | NRP1 (0.73) | NRP1NPR1 | |
| SCHEMBL11094615 | 0.61 | MAPT (0.50) | ALDH1A1HPGDTSHRPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2084140-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | Ark Therapeutics Ltd. (GB) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008040979-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | ARK THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885ALDH1A1 2638/4885SLC10A6 1440/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NRP1 145/4885ALDH1A1 2638/4885SLC10A6 1440/4885 |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885ALDH1A1 2638/4885SLC10A6 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.